nference

Rare, real, and actionable. Today’s Reuters coverage of our new nference study highlights why large-scale observational evidence matter as GLP-1 therapies become part of routine care. The most important finding from the #AI-augmented curation of routine clinical notes is not simply that hair loss can occur. It is that weight loss alone may be an incomplete explanation. After matching patients for achieved weight loss, new-onset alopecia remained more frequent with tirzepatide than semaglutide, 4.24% versus 3.33% (RR: 1.27; P<0.001). Among women, rates were 5.44% versus 3.63%. Patients who developed alopecia were also enriched for thyroid and reproductive-endocrine conditions, while repeated laboratory measurements did not reveal broad depletion of commonly measured vitamins or minerals. For physicians, this means not considering hair loss as simply the price of weight loss alone. For consumers, it means hair loss is uncommon, not inevitable, and deserves individualized counseling and evaluation rather than automatic treatment discontinuation. This is why real-world evidence matters. It complements randomized clinical trials (RCTs) by revealing how benefits and risks differ across apparently similar therapies, the biology unique to each patient , and lived clinical trajectories across large cohorts of diverse patients. Across cardiometabolism and every therapeutic area involving care for complex and chronic conditions, our goal at nference is to move beyond population averages and help physicians and patients make more precise, informed decisions. #AgenticAI #MAIA #hairloss #weightloss #GLP1 #RealWorldEvidence #federated #EHR #AI #Cardiometabolism #Alopecia #PrecisionMedicine #nference

When patients take semaglutide, their dose appears to influence cardiovascular benefits more than how much weight they lose. That's according to a new analysis from researchers with nference.

For many patients considering GLP-1 therapy, one fear sits quietly behind the first prescription: "What happens if I cannot stay on this medication forever?" Today’s thoughtful NBC News coverage by Simar Bajaj gets to the heart of that uncertainty. Our real-world nference study suggests that stopping tirzepatide (Zepbound, Mounjaro) or semaglutide (Wegovy, Ozempic) does not automatically mean regaining all the weight. Most patients maintained their progress six months after their last documented GLP-1 prescription. Importantly, patients who maintained their weight loss were more likely to have received exercise counseling during treatment, suggesting that the habits and support built during GLP-1 therapy may matter long after the final dose. This study is not a promise that weight regain will never happen. It is something equally important: evidence that patients should not be told failure is inevitable. Real life is more complex than discontinuation within a gold-standard randomized clinical trial (RCT) protocol. Patients adapt. Physicians personalize. Biology differs. And real-world uncertainty deserves the best possible real-world science, beyond inferencesdrawn from a controlled setting. RCTs are the necessary first step in bringing a treatment to market, but they are not sufficient on their own to ensure that every patient receives the full benefit they deserve. Grateful to Simar and #NBC for centering the patient experience, and congratulations to my colleagues Gowtham Varma, AJ Venkatakrishnan, Patrick Lenehan and Karthik Murugadoss on getting this important #nference study published in Biology Methods & Protocols by Oxford University Press. NBC News: https://lnkd.in/gxSVixv3

When does successful weight loss begin to become loss of physiologic reserve? Reuters highlighted the new nference study with peer-review ongoing that examined nearly 54,000 adults aged 65 years or older across three settings: #tirzepatide (#Zepbound, #Mounjaro) treatment, other antidiabetic medications, and #bariatric #surgery. Frailty-related conditions were uncommon overall. But when malnutrition, dehydration, appetite loss, or muscle wasting appeared, they marked a profound change in prognosis across all three pathways. Among #tirzepatide-treated adults, #malnutrition was associated with an approximately 25-fold higher risk of death compared with patients who did not develop malnutrition. The corresponding risks were approximately seven-fold with other antidiabetic medications and two-fold after bariatric surgery. Muscle wasting and dehydration followed a similar pattern. The signal was therefore not unique to one drug or one approach to weight loss. But among tirzepatide users, frailty phenotypes rose with greater weight loss, particularly beyond 20%, and often emerged only after several months of treatment. These observational findings do not establish that tirzepatide caused the adverse outcomes. They suggest something more immediately actionable: frailty may be the body’s early warning that intended weight loss is beginning to overlap with physiologic depletion. The future of obesity care cannot measure success only in pounds lost, BMI reduced, or glucose improved. Especially after age 65, we must also ask: Is strength being preserved? Is protein intake adequate? Is hydration maintained? Is independence protected? Powerful weight-loss interventions deserve equally powerful monitoring. As #Medicare access expands via the GLP-1 Bridge Program, the question is no longer only, “How much weight can we help older adults lose?” It is, “How much health and resilience can we help them preserve while they lose it?” Thank you to Nancy Lapid and #Reuters for bringing attention to this timely clinical question. Reuters article: https://lnkd.in/g3Em_AkT #GLP1 #Tirzepatide #BariatricSurgery #Obesity #Diabetes #Frailty #WeightLoss #HealthyAging #Medicare #Geriatrics #RealWorldEvidence #MAIA nference

What if the future of cardiometabolic medicine is healthy longevity? Today, nference announced the first series of publications from the Metabolism Agentic Intelligence Atlas (#MAIA), spanning 15 foundational studies across a federated network of more than 30 million patients: 🌟 https://lnkd.in/ewq6jE-K The central thesis of MAIA is simple, but profound: the future of GLP-1 and precision peptide medicine will be defined by #WholeBody #Spatial #Intelligence, measuring not only weight loss, but organ protection, functional preservation, disease-trajectory change, behavioral modification, legacy benefits, and progress toward healthy longevity. MAIA is a step toward physician-validated autonomous AI agents that accelerate research into #healthy #longevity. Within MAIA, these agents operate with human expert checkpoints, generating prompts, challenging and validating one another’s hypotheses, and mapping incretin therapies, concomitant medicines, and real-world interventions to their molecular mechanisms of action. This enables systematic assessment of potential synergy, antagonism, and signaling-pathway interactions across routine care. The goal is to make prospective clinical studies sharper, more biologically grounded, more patient-centric, and more capable of discovering what several decades of routine care can already teach us. [References enclosed in the Comments] #MAIA #nference #GLP1 #Cardiometabolism #AI #HealthyLongevity #AgenticAI #Innovation #FutureIsHere #FutureIsNow #FutureIsYou

nference recently hosted an incredible #Agentic Immunology event at Raffles Boston, bringing together leaders across biopharma, academia, healthcare, and AI to explore immunology in the age of agentic AI. Relive the experience with our video highlights from a day filled with thoughtful panel discussions, meaningful conversations, and inspiring presentations on how AI, #multimodal data, and real-world evidence can help decode the complexity of the immune system. A sincere thank you to all of our speakers, moderators, and attendees for making the event such a success. Special thanks to Dr. Michal (Mikki) Tal and Dr. Bryan Bryson for their excellent keynote presentations, and to Dr. Tal’s Research Group for leading an inspiring live capillaroscopy demo that brought emerging non-invasive diagnostics to life for the audience. Learn more about nference and our #nSights platform that is enabling the next generation of agentic AI research across all therapeutic areas: https://nference.com/ #AgenticAI #Immunology #AIinBiopharma #RealWorldEvidence #RWD #ClinicalResearch #TranslationalScienc

Great to discuss and hear practical perspectives from experts in the trenches who are building biomedical data and AI systems, at the nference agentic AI for immunology summit.

Thrilled to have participated in the recent panel discussion with Michael J. Steinbaugh, PhD, Dipen Sangurdekar, Felix Francis, PhD , and Sourav Choudhury on Agentic AI in Immunology! 🚀 Riding the vanguard wave of AI-driven healthcare, every clash of ideas and insights is truly exhilarating. Moving forward, I look forward to more frequently share my experiences and insights at the cross-sections of neuroscience, immunology, and AI. I am excited to stand shoulder-to-shoulder with peers as we push boundaries, grow together, and truly translate the power of technology into meaningful contributions - decoding complex biological systems into actions that impact and accelerate drug discovery and development, and ultimately benefit patients worldwide. 🚀🚀 Sincere thanks to the organizers nference, Matthew Hurchik , Nick Hollmer and other for putting together such an incredible event, and to the audience for their warm affirmation and positive feedback. Your recognition is an immense encouragement to me! #nference #AgenticAI #Immunology #PharmaInnovation #DataScience #HealthcareAI #Biotech #Collaboration